Quality Verification of Dendritic Cell-Based Cancer Vaccine
- *Corresponding Author:
- Shigetaka Shimodaira
Center for Advanced Cell Therapy
Shinshu University Hospital 3-1-1 Asahi
Matsumoto, Nagano 390-8621, Japan
E-mail: [email protected]
Received Date: January 30, 2016; Accepted Date: February 16, 2016; Published Date:February 18, 2016
Citation: Shimodaira S, Koya T, Higuchi Y, Okamoto M, Koido S (2016) Quality Verification of Dendritic Cell-Based Cancer Vaccine. Pharm Anal Acta 7:465.doi: 10.4172/2153-2435.1000465
Copyright: © 2016 Shimodaira S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In the era of personalized cancer therapy, immunotherapy is now emerging as a potential option. Therapeutic cancer vaccination has been developed for the induction of an efficient immune response targeting tumor-associated antigens. The efficacy of dendritic cell (DC)-based vaccines is attributed to their ability to induce immunity against cancers. Criteria for the approval of therapeutically active DCs, such as their viability and purity, are here verified based on phenotypic characteristics, linked to their antigen-presenting ability and functional analyses of phagocytosis and pinocytosis. A standardized phenotype of DCs harboring bioactive functions would be useful to provide personalized vaccines for cancer immunotherapy.